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A B S T R A C T
β-thalassemia (β-Thal) is caused by defective β-globin production leading to globin chain imbalance, aggrega-
tion of free alpha chain in developing erythroblasts, reticulocytes, and mature circulating red blood cells. The
hypochromic thalassemic red cells exhibit increased cell dehydration in association with elevated K+ leak and
increased K-Cl cotransport activity, each of which has been linked to globin chain imbalance and related oxi-
dative stress.
We therefore tested the effect of genetic inactivation of K-Cl cotransporters KCC1 and KCC3 in a mouse model
of β-thalassemia intermedia. In the absence of these transporters, the anemia of β-Thal mice was ameliorated, in
association with increased MCV and reductions in CHCM and hyperdense cells, as well as in spleen size. The
resting K+ content of β-Thal red cells was greatly increased, and Thal-associated splenomegaly slightly de-
creased. Lack of KCC1 and KCC3 activity in Thal red cells reduced red cell density and improved β-Thal-asso-
ciated osmotic fragility. We conclude that genetic inactivation of K-Cl cotransport can reverse red cell dehy-
dration and partially attenuate the hematologic phenotype in a mouse model of β-thalassemia.
1. Introduction
β-globin gene mutations associated with β-thalassemia carrier status
affect> 1–5% of the world population concentrated in the
Mediterranean basin and the equatorial belt, with local allele fre-
quencies as high as 30%. These mutations include missense, nonsense
and variably sized indel mutations in both coding and non-coding
regulatory regions of the β-globin gene, causing decreased abundance
of structurally intact β-globin polypeptide, and leading to α/β globin
chain imbalance and consequent precipitation of unassembled or mis-
folded globin chains that cannot assemble into normal hemoglobin α2β2
heterotetramers [19,37,38].
β-thalassemia intermedia manifests as chronic hemolysis, in-
effective erythropoiesis, and iron overload [19,37,38]. Long-term
treatment has until recently been limited to blood transfusion and iron
chelation. Genetic or pharmacological derepression of γ-globin ex-
pression, or controlled genetic or pharmacological suppression of α-
globin expression remain early stage approaches with challenging
safety profiles [19,37,38]. Although hematopoietic stem cell trans-
plantation from a fully matched donor can be curative, even the few
such matches available are accompanied by risks of graft vs. host dis-
ease or rejection [4].
Recent therapeutic options to have entered clinical trial include
activin receptor trap ligands such as sotatercept and luspatercept, and
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JAK2 inhibitors such as ruxolitinib. Iron restriction strategies such as
minihepcidins and TMPRSS6 inhibitors are designed to reduce trans-
fusion requirement and the need for chelation therapy [19,37,38].
Perhaps the most exciting long-term therapeutic development is ex vivo
complementation [39] or gene-editing correction [40] of β-globin
mutations in patient hematopoietic stem cells. However, small molecule
therapies of lower cost and wider availability will remain needed for
treatment of the vast majority of thalassemia patients, especially those
in less developed countries.
In this context, we have readdressed the possible therapeutic utility
of targeting pathological red cell dehydration in thalassemia inter-
media. β-Thalassemic (β-Thal) red cells in humans [9,31] and in mice
[11] exhibit increased cell dehydration in association with elevated K+
leak and elevated K-Cl cotransport activity. Higher mean corpuscular
hemoglobin concentration (MCHC) and lower mean corpuscular vo-
lume (MCV) were found to correlate with greater clinical severity of β/
+ thalassemia [29]. Indeed the increased K+ leak in thalassemia has
been associated with the abundance of intracellular globin aggregates
arising from globin chain imbalance and the resulting oxidative stress
[25]. Increasing red cell Mg content through dietary supplementation
can reduce red cell dehydration in thalassemic mice [11], but sub-
sequent attempts to confirm this result in humans have not shown ef-
ficacy [12]. Currently available small molecule inhibitors of the ele-
vated K-Cl cotransporters of thalassemic red cells are not of adequately
high affinity and specificity to allow clinical use.
To evaluate the possible utility of such K-Cl cotransport inhibitors
for thalassemia, we generated mouse models of thalassemia intermedia
genetically deficient in the erythroid K-Cl cotransporters Kcc1 and Kcc3.
We characterized the hematological indices and K+ transport proper-
ties of the red cells of these mice. We found that genetic and functional
inactivation of the two K-Cl cotransporters KCC1 and KCC3 led to near-
complete rescue of hematocrit, in parallel with increased MCV, de-
creased CHCM and increased osmotic fragility. Loss of KCC activity also
decreased red cell density and increased red cell K content. However,
cellular heterogeneity (RDW) was not decreased, while splenomegaly
was only slightly decreased. Moreover, reticulocyte count was in-
creased, rather than decreased. Thus, the pathological cell dehydration
of circulating thalassemic red cells was substantially reversed by ge-
netic inactivation of the K-Cl cotransporters KCC1 and KCC3.
2. Materials and methods
2.1. Materials
Salts, reagents and solvents were from Sigma-Aldrich (St. Louis,
MO). Staurosporine, wortmannin, PP2 (3-(4-chlorophenyl) 1-(1,1-di-
methylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine), D4476 (4-[4-
(2,3-Dihydro-1,4-benzodioxin-6-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]
benzamide), and DMAT [2-(Dimethylamino)-4,5,6,7-tetrabromo-1H-
benzimidazole] were from Calbiochem (San Diego, CA).
2.2. Mice
Mice were housed in humidity- and temperature-controlled rooms
in the AAALAC-approved Animal Research Facility of Beth Israel
Deaconess Medical Center under IACUC-approved protocols. Hbbth3/+
(β-Thal) transgenic mice originally on the C57BL/6Jx129Ola back-
ground [42] had been bred onto a C57BL6 background. K-Cl co-
transporter-deficient mice Kcc1+/−, Kcc3+/− and Kcc1−/−;Kcc3+/−
(obtained from Prof. Thomas J. Jentsch) were created and genotyped as
described [30]. Thal;Kcc1−/− mice were created by crossing β-Thal
mice with Kcc1−/− mice, then back-crossing Thal;Kcc1+/− mice with
Kcc1−/− mice and selecting the desired genotype. Thal;Kcc1−/
−;Kcc3+/− and Thal;Kcc1−/−;Kcc3−/− mice were generated by
crossing Thal;Kcc1−/− mice with Kcc1−/−;Kcc3+/− mice, with inter-
crossing of progeny to select the desired genotypes. In every mating to
generate β-Thal progeny, the β-Thal allele was provided by a single
parent. Wild type mice used for comparison with knockout mice were
wild type progeny of β-Thal x WT C57BL6/J crosses (WTThal) and of
further generations of β-Thal x WTThal crosses.
As previously observed [30,33], Kcc3−/− mice reached weaning at
22% of predicted Mendelian frequency, and of these 50% survived to
age 6 weeks. Thal;Kcc3−/− mice reached weaning at a frequency 34%
of predicted, but none survived to age 6 weeks. Interestingly, although
Thal;Kcc1−/−;Kcc3−/− mice reached weaning at a similar 30% of
predicted frequency, 93% of weaned mice survived to age 6 weeks.
Thus, further studies were conducted with Thal;Kcc1−/− and with
Thal;Kcc1−/−;Kcc3−/− mice.
2.3. Genotyping
Hbbth3/+ (β-Thal) transgenic mice were generated by “plug and
socket” targeted deletion of both β-major and β-minor genes [42] with
targeted replacement by a construct including human hypoxanthine
phosphoribosyltransferase 1 (HPRT). We therefore followed the Thal
allele with oligos selective for human but not mouse HPRT. Forward
oligo HPRT.F1 (5′-TTCAAGTTGAGTTTGGAAACATCTG-3′) and reverse
oligo HPRT.R2 (5’-TTCAATCACTTCTATTCTTTCCTGC-3′) were an-
nealed at 60 °C and produced a 369 bp PCR product after 35 cycles of
PCR. We included as a PCR reaction positive control the primer pair of
KCC1.E20F (5′-ACCTCCGCCTGGAAGCTGAAG-3′) and KCC1.CtM
(5′-CTCAGGARTAGATGGTGATGACTTC-3′), which yielded a 1297-bp
mouse KCC1 genomic amplification product [30].
2.4. Histology
After terminal exsanguination, spleens were excised and immersion-
fixed overnight at 4 °C in 4% paraformaldehyde in phosphate-buffered
saline (PBS), washed in PBS, then stored at 4 °C in PBS containing
0.02% sodium azide. Paraffin-embedded tissue was sectioned and
stained with hematoxylin-eosin for microscopic examination.
2.5. Preparation of erythrocytes for flux studies
Blood was collected in heparinized syringes by cardiac puncture of
Avertin-anesthetized mice according to protocols approved by the
Institutional Animal Care and Use Committee of Beth Israel Deaconess
Medical Center. Blood was centrifuged at 2500 rpm in 50ml Falcon
tubes for 5min at 4 °C. After careful removal of the buffy coat by as-
piration, packed cells were washed 5 times at 4 °C in ~20 volumes of
wash solution (in mM): 172 Choline Cl, 1 MgCl2, 10 Tris MOPS, pH 7.40
at 4 °C. Cells were suspended to 30–50% cytocrit in wash solution and
kept at 4 °C for same-day use in flux studies. Red blood cell indices were
measured with the ADVIA 120™ hematology analyzer, using mouse
software (Siemens Diagnostic Solutions, Tarrytown, NY) [16,32]. Total
erythrocyte contents of Na+, K+, and Mg2+ were determined in freshly
isolated mouse erythrocytes by atomic absorption spectrophotometry
(AAnalyst 800; Perkin Elmer, Norwalk, CT) [27].
2.6. Erythrocyte K+ fluxes
K-Cl cotransport (KCC) activity was determined as bath chloride-
dependent K+ efflux in erythrocytes exposed to hypotonic swelling in
the presence of 1mM ouabain and 10 μM bumetanide [27,30,32,33].
Freshly isolated erythrocytes were incubated in either isotonic or hy-
potonic solutions containing (in mM) 115 NaCl or Na Sulfamate, 1
MgCl2, 10 glucose, 10 Tris-MOPS pH 7.4 at 37 °C, 1 ouabain, and 0.01
bumetanide (255–265mOsm) or into isotonic NaCl or Na sulfamate
solutions containing (in mM) 160 NaCl, 1 MgCl2, 10 glucose, and 10
Tris-MOPS pH 7.4 at 37 °C.
Aliquots were removed after 5min and 25min incubation at 37 °C
and immediately transferred to precooled 4ml plastic tubes. Post-
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centrifugation supernatant [K+] was calculated from K content mea-
sured by atomic absorption. K+ efflux was calculated from the slope of
the linear regression of K content vs. time. Chloride-dependent KCC
activity was estimated by subtracting K+ efflux in the presence of sul-
famate from that in the presence of chloride. Chloride-dependent KCC
activity measured in isotonic medium was compared with that mea-
sured in hypotonic medium, or with isotonic medium containing added
staurosporine (1 μM) or added urea (500mM).
2.7. Phthalate density profile
Erythrocyte density distribution profiles of freshly obtained whole
blood were measured at 23 °C in microhematocrit tubes containing
phthalate esters of density between 1.060 and 1.108 g/ml [16]. The %
cells of density > X was calculated from the total cell content sedi-
mented below the phthalate oil density boundary in the lower oil zone
divided by the total cell volume. The phthalate oil D50 value is the 50th
%ile of density of the red cell population, and describes alterations in
RBC density profiles [8,10].
2.8. Osmotic fragility measurement
Osmotic fragility of erythrocytes was measured on freshly collected
heparinized blood. RBCs washed 3× with choline wash solution and
once in isotonic saline were resuspended at 10% cytocrit. Aliquots were
suspended in varying concentrations of NaCl and centrifuged 5min at
3000 RPM at 22 °C. A540 was measured in the resultant supernatants
and appropriate controls to calculate values of % RBC lysis. Osmotic
fragility curves were generated by plotting salt concentration vs. %
hemolysis.
2.9. Statistical analysis
All results are expressed as means± SEM. As the data were non-
parametric, they were analyzed by ANOVA with Mann-Whitney or
Kruskall-Wallis non-paired tests using Prism 8 software (GraphPad).
Significance was set at p < .05.
3. Results
3.1. Genetic inactivation of Kcc1 and Kcc3 increases hematocrit and MCV
and reduces dehydration in β-Thal mouse red cells
Genetic inactivation of Kcc1 and Kcc3 resulted in amelioration of
murine β-Thal anemia, whereas the effect of Kcc1 inactivation alone
was much more modest (Table 1). The near-normal hematocrit of
Thal;Kcc1−/−;Kcc3−/− mice was accompanied by increased red cell
mean corpuscular volume (MCV; 53.4 vs. 35.9 fL for Thal) and reduced
red cell values of corpuscular hemoglobin concentration, mean (CHCM;
21.6 vs. 27.5 g/dL). Although β-Thal red cells were not on average
dehydrated compared to WTThal erythrocytes (Table 1), the % of hy-
perdense red cells was elevated in β-Thal mice (3.7% vs 0.2% for WT).
The proportion of hyperdense cells in Thal;Kcc1−/−;Kcc3−/− mice
trended towards lower values as compared to β-Thal mice, but the
comparison did not achieve statistical significance (Table 1).
The elevated red cell volume distribution width (RDW) value of β-
Thal red cells (33.7%) was decreased by combined inactivation of
Kcc1−/− and Kcc3−/− (29.3%), even as accompanied by exacerbated
reticulocytosis (27.8% vs. 18.6% for β-Thal red cells; Table 1). Profiles
of red cell volume and hemoglobin concentration from representative
individual mice are shown in Fig. 1. The left-shifted distribution of
single cell volume in β-Thal vs. WTThal red cells changes was reversed
and exceeded in red cells from a Thal;Kcc1−/−;Kcc3−/− mouse. In
contrast, the left-shifted distribution of single cell hemoglobin con-
centrations in Thal red cells compared with WTThal red cells was further
left-shifted in β-Thal red cells by combined inactivation of Kcc1 and
Kcc3.
The changes induced by combined inactivation of Kcc1−/− and
Kcc3−/− in circulating red cells were qualitatively paralleled by the
smaller relative changes observed in MCV and CHCM values of ADVIA-
defined reticulocyte populations. Thal reticulocyte MCV remained
lower than that of WTThal reticulocytes, even while % hyperdense cells
among ADVIA-defined reticulocytes was slightly increased. However,
combined inactivation of Kcc1−/− and Kcc3−/− in β-Thal red cells
completely rescued reticulocyte MCV to wild-type values (Table 2). The
less dramatically elevated values of RDW and % hyperdense cells in
reticulocytes were not statistically reduced in Thal;Kcc1−/−;Kcc3−/−
mice (Table 2). Inactivation of either or both K-Cl cotransporter genes
exacerbated reticulocytosis in β-Thal mice.
3.2. Genetic inactivation of Kcc1 and Kcc3 increases cation content of Thal
red cells
The greatly elevated MCV of Thal;Kcc1−/−;Kcc3−/− red cells was
paralleled by elevated red cell K content (Table 3). Interestingly, the
elevated Na content also present in Thal red cells was further elevated
in the genetic absence of KCC1 and KCC3. Thal;Kcc1−/−;Kcc3−/− red
cells also displayed elevated Mg content compared to β-Thal (Table 3).
3.3. Combined genetic inactivation of Kcc1 and Kcc3 does not exacerbate
the splenomegaly of β-Thal mice
Fig. 2 demonstrates that the splenomegaly of thalassemic mice is not
to a statistically significant degree further increased by genetic in-
activation of Kcc1, or by incremental haploinsufficiency of Kcc3.
However, combined inactivation of Kcc1 and Kcc3 slightly attenuates
the splenomegaly of β-Thal mice. Histological examination of spleens
from 2.5month old Thal;Kcc1−/−;Kcc3−/− mice revealed congested
Table 1
Erythrocyte indices from WT and β-Thal mice of indicated genotypes. Values are means ± SEM for indicated (n). Hb: hemoglobin; MCV: Mean Corpuscular Volume;
CHCM: Corpuscular Hemoglobin Concentration Mean; RDW: Red cell distribution Width; Hyper: Hyperchromic red cells; Retic: Reticulocytes. ***, p < .0001 vs
WTThal. #, p < .01; ##, p < .001; ###; p < .0001 vs. Thal. One-way ANOVA, Kruskal-Wallis test with Dunn's multiple comparison test.
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red pulp (Fig. 3 A,B,D,E) with hemosiderin-laden macrophages, nu-
cleated erythroid precursors and anucleate RBCs. The spleen from an
older β-Thal mouse exhibited a more developed white pulp together
with continued red pulp congestion (Fig. 2C,F) with more abundant
hemosiderin deposits and trilineage hematopoiesis, including clusters
of megakaryocytes, myeloid, and erythroid precursors.
3.4. Genetic inactivation of Kcc1 and Kcc3 further decreases Thal red cell
density
Although the phthalate density profile of Thal red cells was greatly
left-shifted from that of WTThal red cells (Fig. 4), the proportion of β-
Thal red cells of density≥ 1.1 g/ml was measurable, whereas that of
WT cells was near-zero. β-Thal red cell density was minimally reduced
by inactivation of Kcc1 alone, or with incremental haploinsufficiency of
Kcc3. However, combined inactivation of Kcc1 and Kcc3 led to a dra-
matic left shift of the β-Thal red cell density profile which, nonetheless,
preserved some red cells of density≥ 1.1 g/dL (Fig. 4).
3.5. Genetic inactivation of Kcc1 and Kcc3 partially reverses the reduced
osmotic fragility of β-Thal red cells
β-Thal red cells displayed reduced osmotic fragility compared to
WTThal red cells, with a greatly left-shifted osmotic fragility profile
much flatter than the sigmoidal WT profile (Fig. 5). Genetic inactivation
of Kcc1 alone or with incremental haploinsufficiency of Kcc3 produced
minimal change in β-Thal red cell osmotic fragility. However, combined
inactivation of Kcc1 and Kcc3 partially restored β-Thal red cell osmotic
fragility towards WT levels for the most osmotically resistant 65% of
cells, while maintaining the flattened profile characteristic of β-Thal
cells. The remaining 35% of Thal;Kcc1−/−;Kcc3−/− red cells exhibited
osmotic fragility exceeding that of WT cells, and half of these more
fragile Thal;Kcc1−/−;Kcc3−/− red cells also exceeded the osmotic
fragility of the least fragile β-Thal cells (Fig. 5). Thus, loss of erythroid
KCC activity in β-Thal red cells led to a complex change in osmotic
fragility phenotype.
Fig. 1. Distributions of single red cell volume and hemoglobin concentration from representative mice of the indicated genotypes. At left, hemoglobin concentration
distributions (HC) and volume distributions (Vol) among red cells from individual mice of the indicated genotypes. Inset values of MCV and of CHCM are in white.
Rightmost graphs plot cell volume (Y axis) vs. cell hemoglobin concentration (X axis).
Table 2
Reticulocyte indices from WT and β-Thal mice of indicated genotypes. Values are means ± SEM for indicated (n). MCVr: Mean Corpuscular Volume of reticulocytes;
CHCMr: Corpuscular Hemoglobin Concentration, Mean of reticulocytes; RDWr: Reticulocyte Distribution Width; Hyperr: Hyperchromic reticulocytes. *p < .003; **,








WTThal (61) 58.0 ± 0.4 26.6 ± 0.2 15.4 ± 0.3 0.6 ± 0.1
Thal (88) 52.2 ± 0.4*** 24.0 ± 0.2*** 20.5 ± 0.2*** 0.9 ± 0.1**
Thal;Kcc1−/− (21) 53.6 ± 0.7 24.1 ± 0.3 20.4 ± 0.4 1.3 ± 0.3
Thal;Kcc1−/−;Kcc3+/− (25) 52.9 ± 0.6 24.3 ± 0.3 20.8 ± 0.3 1.3 ± 0.2
Thal;Kcc1−/−;Kcc3−/− (5) 58.4 ± 1.2* 22.3 ± 0.4 19.6 ± 0.6 0.5 ± 0.4
B.E. Shmukler, et al. Blood Cells, Molecules and Diseases 81 (2020) 102389
4
3.6. K-Cl cotransport activity in β-Thal red cells without and with genetic
inactivation of Kcc1 and Kcc3
Although basal KCC activity (defined as Cl−-dependent K+ efflux in
isotonic medium) was indistinguishable between WTThal and β-Thal red
cells, KCC activity stimulated by hypotonicity (HYPO) or by 1 μM
staurosporine (Stauro) was higher in β-Thal than in WT red cells
(Fig. 6). In contrast, urea-stimulated KCC activity was not higher in β-
Thal than in WT red cells. Genetic inactivation of Kcc1 in β-Thal red
cells reduced staurosporine-stimulated KCC activity to WT levels, while
further increasing urea-stimulated KCC activity above WT and β-Thal
levels (Fig. 6).
Red cells from Thal;Kcc1−/−;Kcc3+/− mice retained stimulation by
hypotonicity and by staurosporine at lower levels than in Thal;Kcc1−/−
red cells, whereas stimulation by urea was only minimally reduced.
However, combined inactivation of Kcc1 and Kcc3 abrogated stimula-
tion of K-Cl cotransport by all three stimulatory conditions (Fig. 6).
The measurements of KCC activity summarized in Fig. 6 were lim-
ited to experiments in which each red cell sample was tested in the
presence of Cl−-containing media and SFA-containing media. Com-
bined ion transport results from the entire study, including experiments
in which red cells were tested in the presence of either Cl−- or SFA-
containing media, but not both (due to blood volume limitations or
other reasons), are presented in Supplemental Figs. 1 and 2.
3.7. Kinase inhibitor effects on KCC activity in β-Thal red cells
Hypotonic stimulation of KCC activity in normal human red cells is
mediated in large part by inhibition of KCC phosphorylation mediated
by the WNK1-OSR1 kinase cascade [26] [34,43]. The wide-spectrum,
ATP-competitive kinase inhibitor, staurosporine, has been shown di-
rectly to inhibit WNK1 [41], and as shown in Fig. 6 and Supplemental
Fig. 3 also activates KCC activity in β-Thal red cells. PP1 and PP2, wide
spectrum Src family tyrosine kinase inhibitors, also inhibit WNK1 di-
rectly [41]. PP2 activates KCC in β-Thal red cells, but to a lesser degree
than staurosporine. Although evidence of wortmannin-sensitive Akt
phosphorylation and NOS activation in red cells has been reported
[22,36], exposure of β-Thal red cells to the PI3-kinase inhibitor wort-
mannin failed to stimulate KCC activity in isotonic medium. In addition,
CK1 inhibitor D4476 and CK2 inhibitor DMAT failed to stimulate KCC
activity in isotonic medium. The direct effects of these inhibitors in the
presence or absence of bath Cl− (with SFA substitution) are presented
in Supplemental Fig. 3.
4. Discussion
β-thalassemic red cells of humans [9,29,31] and mice [11] have
been reported to be dehydrated, with decreased K content and in-
creased K+ leak mediated by elevated K-Cl cotransport activity (usually
without elevation of KCNN4 activity). Elevated MCHC and lower MCV
correlate with increased clinical severity of β/+ thalassemia [29], in
association with increased intracellular globin chain aggregation.
Red cell dehydration predisposes to increased clinical severity in
sickle cell disease by shortening the delay time for the polymerization
of deoxyhemoglobin S that causes red cell sickling. Human sickle red
cells exhibit elevated KCNN4 and KCC activities. Inhibition of red cell
dehydration by the KCNN4 inhibitor senicapoc in Phase 2 and 3 trials
increased blood hemoglobin by nearly 1 g/dL [5,6]. Inhibitors of red
cell KCC are not of sufficiently high affinity and selectivity for clinical
use, but genetic inactivation of KCC1 and KCC3 was shown to reduce
red cell dehydration in a mouse model of sickle cell disease [30]. In-
cremental inactivation of KCNN4 further reduced and reversed red cell
dehydration in SAD mice [33].
We tested here the hypothesis that Kcc1 and Kcc3 are major de-
terminants of the erythrocyte ion composition and volume character-
istics in a mouse model of thalassemia. We found that the reduced red
cell MCV of our β-Thal mouse strain was unaccompanied by dehydra-
tion of the cell population compared to WTThal red cells, but displayed
increased % of hyperdense cells. However, the reduced hematocrit of β-
Thal mice was substantially elevated by genetic inactivation of ery-
throid K-Cl cotransport, accompanied by greatly elevated MCV and
decreased CHCM, reduction in % hyperdense cells, and greatly in-
creased β-Thal red cell K content to normal or above-normal levels. The
reduced red cell density of thalassemic red cells (vs. WT) was little al-
tered by absence of KCC1 or by incremental haploinsufficiency of KCC3,
but further reduced by the combined absence of KCC1 and KCC3
(Fig. 4). The dramatically left-shifted and flattened osmotic fragility
curve of β-Thal red cells (vs. WT) was similarly little altered by lack of
KCC1 or by incremental haploinsufficiency of KCC3. However, com-
plete lack of KCC1 and KCC3 in Thal red cells right-shifted the osmotic
fragility curve. This right shift partially restored osmotic fragility in the
majority of cells towards the WT condition, in a manner consistent with
Table 3
Erythrocyte ion contents from WT and β-Thal mice of indicated genotypes. Values are mean ± SEM of (n) samples. Ion content was measured by atomic








WTThal 444.1 ± 8.0 (19) 20.8 ± 0.4 (18) 9.7 ± 0.6 (6)
Thal 452 ± 6.7 (37) 30.3 ± 1.0* (38) 13.9 ± 1.3 (6)
Thal;Kcc1−/− 444.2 ± 6.2 (28) 38.4 ± 1.1** (27) 17.9 ± 1.7 (5)
Thal; Kcc1−/−;Kcc3+/− 467.5 ± 5.3 (23) 38.9 ± 0.7** (21) 15.8 ± 0.5 (15)
Thal;Kcc1−/−;Kcc3−/− 640.1 ± 14.0*** (13) 42.4 ± 2.4** (13) 21.2 ± 0.9** (9)
Fig. 2. Spleen-body weight ratio of WT and β-Thal mice of indicated genotypes.
Values represent mean ± SEM for (n) mice.
*, p < .0001 vs. WTThal (ANOVA, non-parametric Kruskal-Wallis. Thal; Kcc1−/
−;Kcc3+/− vs Thal;Kcc1−/−;Kcc3−/−; #, p < .001 vs. Thal;Kcc1−/−;Kcc3+/−
(Mann-Whitney test, non-paired).
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the corresponding increase in MCV. However, the small fraction of the
most osmotically sensitive Thal;Kcc1−/−;Kcc3−/− red cells exceeded
the osmotic fragility of intact Thal red cells (Fig. 5), suggesting in-
creased membrane fragility perhaps related to loss of KCC-associated
membrane scaffolding/signaling or other cytoskeletal functions, pos-
sibly leading to reduced surface area and/or increased membrane lea-
kiness.
Fig. 3. Spleen histology. Hematoxylin-eosin-stained sections of spleens from two Thal;Kcc1−/−;Kcc3−/− mice, aged 2.5months (A,B; 10× magnification) show
congested red pulp. The 60×-magnified photomicrographs (D,E) reveal abundant hemosiderin-laden macrophages with golden-brown pigment, nucleated erythroid
precursors and anucleate RBCs. The spleen of a β-Thal mouse aged 5.7months (C, 10×) shows a more developed white pulp along with congested red pulp. At 60×
magnification (F) the β-thal spleen reveals abundant hemosiderin deposits and trilineage hematopoiesis, including clusters of megakaryocytes, myeloid and erythroid
precursors. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 4. Red cell phthalate density profiles as function of genotype. A. Red cells
from WTThal (black triangles) and β-Thal mice (open square) compared with red
cells from Thal;Kcc1−/− (open triangles), Thal;Kcc1−/−;Kcc3+/− (black cir-
cles), and Thal;Kcc1−/−;Kcc3−/− mice (open circles). Values are means± SEM
for (n) independently tested pooled samples of indicated genotype.
Fig. 5. Red cell susceptibility to osmotic lysis as function of genotype. Osmotic
lysis curves of red cells from WTThal mice (black diamonds) compared with
those of red cells from β-Thal mice (open triangles), Thal;Kcc1−/− mice (black
circles), Thal;Kcc1−/−;Kcc3+/− mice (open circles), and Thal;Kcc1−/−;Kcc3−/
− mice (open squares). Values are means ± SEM for (n) independently tested
pooled samples from each genotype.
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4.1. Splenomegaly and reticulocytosis
The splenomegaly of β-Thal mice was not significantly affected by
genetic inactivation of Kcc1 or by additional heterozygosity for Kcc3,
but was slightly improved by combined inactivation of Kcc1 and Kcc3.
Thal;Kcc1−/−;Kcc3−/− spleens were remarkable for erythroid con-
gestion, and numerous hemosiderin-laden erythroblasts, indicative of
extramedullary hematopoiesis. The increased reticulocytosis of Thal;
Kcc1−/−;Kcc3−/− mice could reflect attenuation of ineffective ery-
thropoiesis, as perhaps suggested by the splenic erythroid hyperplasia.
Consistent with this possibility is the increased calculated value for
mean corpuscular hemoglobin (MCH) in Thal red cells lacking both
KCC1 and KCC3 (not shown). However, such an interpretation might
contrast with our previous report [14] that levels of KCC1 and KCC3
mRNAs and KCC polypeptides increased in cultured human CD34+
normal and thalassemic erythropoietic precursors during late-stage er-
ythopoiesis. Moreover, treatment of thalassemic erythropoietic pre-
cursors with K-Cl cotransport inhibitor DIOA blocked in vitro differ-
entiation at the orthochromatic normoblast stage and upregulated p21
and caspase 8, accompanied (in both cell models) by cyclin-D upregu-
lation and reduction in S-phase cells [14]. Further study will be re-
quired to test if these changes occur during murine erythroid devel-
opment in the genetic absence of KCC1 and KCC3. Nonetheless, the
failure of genetic inactivation of KCC1 and KCC3 to correct the re-
ticulocytosis of this Thal mouse model suggests that monotherapy with
small molecule KCC inhibitors will not likely reduce the hemolysis,
erythroid turnover, and resultant iron overload underlying much of the
chronic pathology of β-thalassemia intermedia.
4.2. Red cell ion content
We found that β-Thal (HbbTh3/+) red cell ion contents differed from
those previously reported, as compared to WT cell ion contents. Thus,
in ENU-mutated HbbThal/Thal DBA2/J mice [35] subsequently bred into
the C57BL6/J background [11,15,28], the K content of β-Thal red cells
from HbbThal/Thal on the C57BL/6 J background was much lower than
that of corresponding WT red cells. In a previous report on HbbTh3/+
mice 4–6months of age, red cell K content was less dramatically de-
creased compared to that in C57Bl6/J red cells [17]. However, we
found that HbbTh3/+ red cell K content in our colony was equivalent to
that of WTThal cells. As the average K content of the circulating red cell
population includes both dehydrated cells with low K and young over-
hydrated cells with high K, these components of the population may
vary across the various β-Thal mouse lines. Nevertheless, the K content
of β-Thal red cells was dramatically increased by genetic inactivation of
Kcc1 and Kcc3, resembling the increase in sickle red cell K content
produced by similar genetic ablation in the SAD mouse model of sickle
cell disease [33].
The increased β-Thal red cell K content resulting from combined
genetic inactivation of Kcc1 and Kcc3 was accompanied by increased
intracellular contents of both Na and Mg. This result differed from the
unchanged Na and Mg contents of red cells from HbbThal/Thal mice on
the C57BL/6J background [11,15] or the previously reported statisti-
cally insignificant increase in Na content of HbbTh3/+ red cells [17].
The increased Mg content in Thal;Kcc1−/−;Kcc3−/− red cells in our
study is consistent with the reduced inward Na+ gradient, which would
decrease the inward Na+ driving force driving red cell Mg2+ efflux
mediated by Na+/Mg2+ exchange activity.
Fig. 6. K-Cl cotransport activity in WT, Thal, Thal;Kcc1−/−, Thal;Kcc1−/−;Kcc3+/−, and Thal;Kcc1−/−;Kcc3−/− erythrocytes. Chloride-dependent net K+ efflux
from mouse erythrocytes of the indicated genotypes was measured in isotonic medium (ISO), hypotonic medium (Hypo), isotonic medium containing 1 μM staur-
osporine (Stauro), and isotonic medium containing added 500mM urea (Urea). Values are means ± SEM for (n) independent experiments at the indicated condition,
representing the difference between the higher K+ efflux measured in chloride and the lower K+ efflux measured in sulfamate in each paired experiment (see
Supplementary Figs. 1 and 2). *, p < .0011 vs. WT; **, p < .0001 vs. WT; #, p < .0017 vs. Thal; ##, p= .0004 vs. Thal; non-parametric Mann-Whitney test. §,
p < .019; §§, p < .0025;
§§§, p < .0001, all vs. Thal;Kcc1−/−;Kcc3+/−; non-parametric Mann-Whitney test. (K-Cl cotransport activity in isotonic medium was higher in Thal;Kcc1−/−;Kcc3+/
− cells than in either Thal (p= .0014) or WTThal cells (p= .0011; p values absent from Fig. 6 for clarity). In contrast, isotonic activity of Thal;Kcc1−/−;Kcc3−/− cells
did not differ statistically from isotonic activity of Thal or WTThal cells.)
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The elevated Na content could reflect inhibition of Na+,K+-ATPase
activity by elevated intracellular Mg2+, as reported in normal human
red cells [20]. Indeed, phenylhydrazine treatment of normal human red
cells to mimic the oxidative damage of thalassemia also decreased
Na+,K+-ATPase activity [25]. In contrast, red cell membranes [24] and
intact red cells [25] from human β-thalassemia intermedia patients
exhibited increased Na+,K+-ATPase activity. However, this increased
Na+,K+-ATPase activity in intact cells was greatly reduced by dietary
Mg supplementation, in parallel with increased cell Na content [12].
The elevated Na content of mouse Thal;Kcc1−/−;Kcc3−/− red cells in
the current study might reflect elevated oxidative stress [1,23] in our β-
Thal colony at some point during erythropoiesis [14] and/or increased
mechanical stress experienced by circulating cells of larger volume
[25].
4.3. KCC regulation in β-Thal red cells
The stimulation of mouse β-Thal red cell KCC activity by hypoto-
nicity and by staurosporine confirms previous reports of De Franceschi
et al. [17], which established a role for oxidative membrane damage in
increasing both basal and stimulated KCC activity. Our current data
further establish the partial dependence of staurosporine-stimulated
KCC activity on the Kcc1 gene product (Fig. 6). These data also de-
monstrate for the first time that urea also stimulates KCC activity in
mouse β-Thal red cells, but (unlike for staurosporine or hypotonicity)
not to a greater degree than in WT red cells. Curiously, urea-stimulated
KCC activity in β-Thal red cells was potentiated by solitary genetic
inactivation of Kcc1, whereas KCC stimulation by hypotonicity was
unaffected by loss of Kcc1 (Fig. 6).
4.4. Kinase inhibitor-mediated KCC activation in β-Thal red cells
KCC activity in β-Thal red cells was stimulated by the nonspecific
kinase inhibitor, staurosporine and, to a lesser extent, by the Src family
kinase inhibitor, PP2 (Supplemental Fig. 3). PP2 stimulation of K-Cl
cotransport was previously demonstrated in WT mouse red cells, but
was shown not to further stimulate the already elevated level of red cell
K-Cl cotransport in the SAD mouse model of sickle cell disease [18].
Both staurosporine and PP2 can also inhibit WNK1 kinase [41], which
is active in normal human red cells as a regulator of erythroid KCC
proteins [26] and NKCC1 [43]. PP2-mediated inhibition of Src family
kinases also contributes to KCC activation by increasing activity and
decreasing membrane localization of protein phosphatases −1 and −2
[7,13].
The inability of D4476 and DMAT to stimulate β-Thal red cell KCC
makes a stimulatory role for casein kinases unlikely. Demonstrated
cross-inhibition of p38-MAPK by D4476 and of Pim kinases by DMAT
further suggests lack of a KCC stimulatory role for these erythroid ki-
nases, both of which function during erythropoiesis, and (in the case of
p38-MAPK) persist in circulating erythrocytes [3,21]. The inability of
wortmannin to stimulate β-Thal red cell KCC activity makes a stimu-
latory role for phosphatidylinositol-3-kinase unlikely. Cross-inhibition
of PLK1 (polo-like kinase-1) by wortmannin additionally suggests lack
of a KCC stimulatory role for PLK1, which (at least by pharmacological
evidence) remains active in circulating normal human red cells [2].
In summary, genetic ablation of Kcc1 and Kcc3 in a mouse model of
thalassemia increased indices of red cell hydration, but was accom-
panied by elevated reticulocytosis and complex effects on red cell os-
motic fragility. We conclude that KCl cotransport activity encoded by
the KCC polypeptide products of the Kcc1 and Kcc3 genes is a major
determinant of red cell dehydration in the HbbTh3/+ mouse model of β-
thalassemia minor. Additional experiments will be required to explore
the possibility, in light of the heterogeneous changes in Thal;Kcc1−/
−;Kcc3−/− mouse red cell osmotic fragility, that the concomitant in-
crease in reticulocytosis may in part reflect attenuation of ineffective
erythropoiesis and/or prolongation of thalassemic erythrocyte
circulating half-life for at least a fraction of these cells.
Contributions
SLA, BES, and AR designed the study. CB, LDF, MBR, and CAH
provided genetically modified mice. BES, KN, EK, AH, JA, and BL
performed experiments and collected data. AR, BES, CB and SLA ana-
lyzed data. The manuscript was drafted by BES, AR, and SLA and re-
viewed by all co-authors.
Acknowledgements
This work was supported by NIH grant HL077765 and funds from
QUEST Diagnostics awarded to SLA. We thank Prof. Thomas J. Jentsch,
in whose laboratory the Kcc1-/- and Kcc3-/- mice were originally cre-
ated.
Declaration of competing interest
JM and JGW are employees of QUEST Diagnostics. LMS is a con-
sultant to QUEST Diagnostics. SLA received research funds from QUEST
Diagnostics.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bcmd.2019.102389.
References
[1] R. Advani, E. Rubin, N. Mohandas, S.L. Schrier, Oxidative red blood cell membrane
injury in the pathophysiology of severe mouse beta-thalassemia, Blood 79 (1992)
1064–1067.
[2] A. Al Mamun Bhuyan, A.K.M. Ashiqul Haque, I. Sahu, H. Cao, M.S.D. Kormann,
F. Lang, Inhibition of suicidal erythrocyte death by Volasertib, Cell. Physiol.
Biochem. 43 (2017) 1472–1486.
[3] M.A. Alfhili, D.A. Weidner, M.H. Lee, Disruption of erythrocyte membrane asym-
metry by triclosan is preceded by calcium dysregulation and p38 MAPK and RIP1
stimulation, Chemosphere 229 (2019) 103–111.
[4] E. Angelucci, S. Matthes-Martin, D. Baronciani, F. Bernaudin, S. Bonanomi,
M.D. Cappellini, J.H. Dalle, P. Di Bartolomeo, C.D. de Heredia, R. Dickerhoff,
C. Giardini, E. Gluckman, A.A. Hussein, N. Kamani, M. Minkov, F. Locatelli,
V. Rocha, P. Sedlacek, F. Smiers, I. Thuret, I. Yaniv, M. Cavazzana, C. Peters,
E.I. Error, E.P.W. Parties, Hematopoietic stem cell transplantation in thalassemia
major and sickle cell disease: indications and management recommendations from
an international expert panel, Haematologica 99 (2014) 811–820.
[5] K.I. Ataga, M. Reid, S.K. Ballas, Z. Yasin, C. Bigelow, L.S. James, W.R. Smith,
F. Galacteros, A. Kutlar, J.H. Hull, J.W. Stocker, Investigators ICAS, Improvements
in haemolysis and indicators of erythrocyte survival do not correlate with acute
vaso-occlusive crises in patients with sickle cell disease: a phase III randomized,
placebo-controlled, double-blind study of the Gardos channel blocker senicapoc
(ICA-17043), Br. J. Haematol. 153 (2011) 92–104.
[6] K.I. Ataga, W.R. Smith, L.M. De Castro, P. Swerdlow, Y. Saunthararajah, O. Castro,
E. Vichinsky, A. Kutlar, E.P. Orringer, G.C. Rigdon, J.W. Stocker, Investigators ICA,
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in pa-
tients with sickle cell anemia, Blood 111 (2008) 3991–3997.
[7] I. Bize, B. Guvenc, A. Robb, G. Buchbinder, C. Brugnara, Serine/threonine protein
phosphatases and regulation of K-Cl cotransport in human erythrocytes, Am. J.
Phys. 277 (1999) C926–C936.
[8] C. Brugnara, L. De Franceschi, S.L. Alper, Ca(2+)-activated K+ transport in ery-
throcytes. Comparison of binding and transport inhibition by scorpion toxins, J.
Biol. Chem. 268 (1993) 8760–8768.
[9] A. Bunyaratvej, S. Fucharoen, A. Greenbaum, N. Mohandas, Hydration of red cells
in alpha and beta thalassemias differs. A useful approach to distinguish between
these red cell phenotypes, Am. J. Clin. Pathol. 102 (1994) 217–222.
[10] D. Danon, V. Marikovsky, Determination of density distribution of red cell popu-
lation, J. Lab. Clin. Med. 64 (1964) 668–674.
[11] L. De Franceschi, C. Brugnara, Y. Beuzard, Dietary magnesium supplementation
ameliorates anemia in a mouse model of beta-thalassemia, Blood 90 (1997)
1283–1290.
[12] L. De Franceschi, M.D. Cappellini, G. Graziadei, F. Manzato, O. Olivieri,
R. Corrocher, G. Fiorelli, Y. Beuzard, C. Brugnara, The effect of dietary magnesium
supplementation on the cellular abnormalities of erythrocytes in patients with beta
thalassemia intermedia, Haematologica 83 (1998) 118–125.
[13] L. De Franceschi, L. Fumagalli, O. Olivieri, R. Corrocher, C.A. Lowell, G. Berton,
Deficiency of Src family kinases Fgr and Hck results in activation of erythrocyte K/
B.E. Shmukler, et al. Blood Cells, Molecules and Diseases 81 (2020) 102389
8
Cl cotransport, J. Clin. Invest. 99 (1997) 220–227.
[14] L. De Franceschi, L. Ronzoni, M.D. Cappellini, F. Cimmino, A. Siciliano, S.L. Alper,
V. Servedio, C. Pozzobon, A. Iolascon, K-CL co-transport plays an important role in
normal and beta thalassemic erythropoiesis, Haematologica 92 (2007) 1319–1326.
[15] L. de Franceschi, P. Rouyer-Fessard, S.L. Alper, H. Jouault, C. Brugnara, Y. Beuzard,
Combination therapy of erythropoietin, hydroxyurea, and clotrimazole in a beta
thalassemic mouse: a model for human therapy, Blood 87 (1996) 1188–1195.
[16] L. De Franceschi, N. Saadane, M. Trudel, S.L. Alper, C. Brugnara, Y. Beuzard,
Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and re-
verses erythrocyte dehydration in transgenic SAD mice. A model for therapy of
sickle cell disease, J. Clin. Invest. 93 (1994) 1670–1676.
[17] L. de Franceschi, F. Turrini, M. Honczarenko, K. Ayi, A. Rivera, M.D. Fleming,
T. Law, F. Mannu, F.A. Kuypers, A. Bast, W.J. van der Vijgh, C. Brugnara, In vivo
reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia,
Haematologica 89 (2004) 1287–1298.
[18] L. De Franceschi, E. Villa-Moruzzi, A. Biondani, A. Siciliano, C. Brugnara, S.L. Alper,
C.A. Lowell, G. Berton, Regulation of K-Cl cotransport by protein phosphatase
1alpha in mouse erythrocytes, Pflugers Arch. 451 (2006) 760–768.
[19] A. El-Beshlawy, M. El-Ghamrawy, Recent trends in treatment of thalassemia, Blood
Cells Mol. Dis. 76 (2019) 53–58.
[20] P.W. Flatman, V.L. Lew, The magnesium dependence of sodium-pump-mediated
sodium-potassium and sodium-sodium exchange in intact human red cells, J.
Physiol. 315 (1981) 421–446.
[21] S. Gatidis, C. Zelenak, A. Fajol, E. Lang, K. Jilani, D. Michael, S.M. Qadri, F. Lang,
p38 MAPK activation and function following osmotic shock of erythrocytes, Cell.
Physiol. Biochem. 28 (2011) 1279–1286.
[22] L. Kuck, M. Grau, W. Bloch, M.J. Simmonds, Shear stress ameliorates superoxide
impairment to erythrocyte deformability with concurrent nitric oxide synthase
activation, Front. Physiol. 10 (36) (2019).
[23] A. Matte, P.S. Low, F. Turrini, M. Bertoldi, M.E. Campanella, D. Spano, A. Pantaleo,
A. Siciliano, L. De Franceschi, Peroxiredoxin-2 expression is increased in beta-
thalassemic mouse red cells but is displaced from the membrane as a marker of
oxidative stress, Free Radic. Biol. Med. 49 (2010) 457–466.
[24] L. Morle, E. Dorleac, N. Alloisio, P. Jaccoud, P. Colonna, D. Bachir, J. Delaunay,
Kinetic alterations of the red cell membrane phosphatase in alpha- and beta-tha-
lassemia, Am. J. Hematol. 13 (1982) 269–282.
[25] O. Olivieri, L. De Franceschi, M.D. Capellini, D. Girelli, R. Corrocher, C. Brugnara,
Oxidative damage and erythrocyte membrane transport abnormalities in thalasse-
mias, Blood 84 (1994) 315–320.
[26] J. Rinehart, Y.D. Maksimova, J.E. Tanis, K.L. Stone, C.A. Hodson, J. Zhang,
M. Risinger, W. Pan, D. Wu, C.M. Colangelo, B. Forbush, C.H. Joiner, E.E. Gulcicek,
P.G. Gallagher, R.P. Lifton, Sites of regulated phosphorylation that control K-Cl
cotransporter activity, Cell 138 (2009) 525–536.
[27] A. Rivera, R.Y. Zee, S.L. Alper, L.L. Peters, C. Brugnara, Strain-specific variations in
cation content and transport in mouse erythrocytes, Physiol. Genomics 45 (2013)
343–350.
[28] P. Rouyer-Fessard, K. Leroy-Viard, C. Domenget, A. Mrad, Y. Beuzard, Mouse beta
thalassemia, a model for the membrane defects of erythrocytes in the human dis-
ease, J. Biol. Chem. 265 (1990) 20247–20251.
[29] D. Rund, D. Filon, N. Strauss, E.A. Rachmilewitz, A. Oppenheim, Mean corpuscular
volume of heterozygotes for beta-thalassemia correlates with the severity of
mutations, Blood 79 (1992) 238–243.
[30] M.B. Rust, S.L. Alper, Y. Rudhard, B.E. Shmukler, R. Vicente, C. Brugnara,
M. Trudel, T.J. Jentsch, C.A. Hubner, Disruption of erythroid K-cl cotransporters
alters erythrocyte volume and partially rescues erythrocyte dehydration in SAD
mice, J. Clin. Invest. 117 (2007) 1708–1717.
[31] S.L. Schrier, E. Rachmilewitz, N. Mohandas, Cellular and membrane properties of
alpha and beta thalassemic erythrocytes are different: implication for differences in
clinical manifestations, Blood 74 (1989) 2194–2202.
[32] B.E. Shmukler, A. Hsu, J. Alves, M. Trudel, M.B. Rust, C.A. Hubner, A. Rivera,
S.L. Alper, N-ethylmaleimide activates a Cl(−)-independent component of K(+)
flux in mouse erythrocytes, Blood Cells Mol. Dis. 51 (2013) 9–16.
[33] B.E. Shmukler, A. Rivera, P. Bhargava, K. Nishimura, A. Hsu, E.H. Kim, M. Trudel,
M.B. Rust, C.A. Hubner, C. Brugnara, S.L. Alper, Combined genetic disruption of K-
Cl cotransporters and Gardos channel KCNN4 rescues erythrocyte dehydration in
the SAD mouse model of sickle cell disease, Blood Cells Mol. Dis. 79 (2019) 102346.
[34] B. Sid, L. Miranda, D. Vertommen, B. Viollet, M.H. Rider, Stimulation of human and
mouse erythrocyte Na(+)-K(+)-2Cl(−) cotransport by osmotic shrinkage does not
involve AMP-activated protein kinase, but is associated with STE20/SPS1-related
proline/alanine-rich kinase activation, J. Physiol. 588 (2010) 2315–2328.
[35] L.C. Skow, B.A. Burkhart, F.M. Johnson, R.A. Popp, D.M. Popp, S.Z. Goldberg,
W.F. Anderson, L.B. Barnett, S.E. Lewis, A mouse model for beta-thalassemia, Cell
34 (1983) 1043–1052.
[36] F. Suhr, J. Brenig, R. Muller, H. Behrens, W. Bloch, M. Grau, Moderate exercise
promotes human RBC-NOS activity, NO production and deformability through Akt
kinase pathway, PLoS One 7 (2012) e45982.
[37] A.T. Taher, D.J. Weatherall, M.D. Cappellini, Thalassaemia, Lancet 391 (2018)
155–167.
[38] S.L. Thein, Molecular basis of beta thalassemia and potential therapeutic targets,
Blood Cells Mol. Dis. 70 (2018) 54–65.
[39] A.A. Thompson, M.C. Walters, J. Kwiatkowski, J.E.J. Rasko, J.A. Ribeil, S. Hongeng,
E. Magrin, G.J. Schiller, E. Payen, M. Semeraro, D. Moshous, F. Lefrere, H. Puy,
P. Bourget, A. Magnani, L. Caccavelli, J.S. Diana, F. Suarez, F. Monpoux, V. Brousse,
C. Poirot, C. Brouzes, J.F. Meritet, C. Pondarre, Y. Beuzard, S. Chretien, T. Lefebvre,
D.T. Teachey, U. Anurathapan, P.J. Ho, C. von Kalle, M. Kletzel, E. Vichinsky,
S. Soni, G. Veres, O. Negre, R.W. Ross, D. Davidson, A. Petrusich, L. Sandler,
M. Asmal, O. Hermine, M. De Montalembert, S. Hacein-Bey-Abina, S. Blanche,
P. Leboulch, M. Cavazzana, Gene therapy in patients with transfusion-dependent
beta-thalassemia, N. Engl. J. Med. 378 (2018) 1479–1493.
[40] Y. Wu, J. Zeng, B.P. Roscoe, P. Liu, Q. Yao, C.R. Lazzarotto, K. Clement, M.A. Cole,
K. Luk, C. Baricordi, A.H. Shen, C. Ren, E.B. Esrick, J.P. Manis, D.M. Dorfman,
D.A. Williams, A. Biffi, C. Brugnara, L. Biasco, C. Brendel, L. Pinello, S.Q. Tsai,
S.A. Wolfe, D.E. Bauer, Highly efficient therapeutic gene editing of human hema-
topoietic stem cells, Nat. Med. 25 (2019) 776–783.
[41] Y.I. Yagi, K. Abe, K. Ikebukuro, K. Sode, Kinetic mechanism and inhibitor char-
acterization of WNK1 kinase, Biochemistry 48 (2009) 10255–10266.
[42] B. Yang, S. Kirby, J. Lewis, P.J. Detloff, N. Maeda, O. Smithies, A mouse model for
beta 0-thalassemia, Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 11608–11612.
[43] S. Zheng, N.A. Krump, M.M. McKenna, Y.H. Li, A. Hannemann, L.J. Garrett,
J.S. Gibson, D.M. Bodine, P.S. Low, Regulation of erythrocyte Na(+)/K(+)/2Cl(−)
cotransport by an oxygen-switched kinase cascade, J. Biol. Chem. 294 (2019)
2519–2528.
B.E. Shmukler, et al. Blood Cells, Molecules and Diseases 81 (2020) 102389
9
